Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study
Kieron Dunleavy, Michelle A. Fanale, Jeremy S. Abramson, Ariela Noy, Paolo Fabrizio Caimi, Stefania Pittaluga, Samir Parekh, Ann Lacasce, John W. Hayslip, Deepa Jagadeesh, Sunil Nagpal, Mary Jo Lechowicz, Rakesh Gaur, Andrea Lucas, Christopher Melani, Mark Roschewski, Seth M. Steinberg, Elaine S. Jaffe, Brad Kahl, Jonathan W. FriedbergRichard F. Little, Nancy L. Bartlett, Wyndham H. Wilson
Research output: Contribution to journal › Article › peer-review
166Scopus
citations
Fingerprint
Dive into the research topics of 'Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study'. Together they form a unique fingerprint.